Publication

The "complex-in-a-complex" cations [(acac)2M.cntnd.Ru6-(p-iPrC6H4Me)6(tpt)2(dhbq)3]6+: a trojan horse for cancer cells

Paul Joseph Dyson, Anna Katherine Renfrew
2008
Journal Articles

Abstract

The cytotoxicities of the large cationic arene-ruthenium prismatic cage [Ru6(p-iPrC6H4Me)6(tpt)2(dhbq)3]6+ (tpt = 2,4,6-tris(pyridin-4-yl)-1,3,5-triazine, dhbq = 2,5-dihydroxy-1,4-benzoquinolato; 16+), and its "complex-in-a-complex" derivs. [(acac)2M-1]6+ (M = Pd, Pt; acac = acetylacetonate), are evaluated in comparison with free [M(acac)2]. The differences in cytotoxicity suggest that, like a "Trojan Horse", leaching of the guest from the cage once inside a cell accelerates and increases the cytotoxic effect.

Official source

https://infoscience.epfl.ch/entities/publication/e973e8d2-bd09-47fb-96e7-36a20c049521

About this result

This page is automatically generated and may contain information that is not correct, complete, up-to-date, or relevant to your search query. The same applies to every other page on this website. Please make sure to verify the information with EPFL's official sources.

Graph Chat

Chat with Graph Search

Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.

DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.

The "complex-in-a-complex" cations [(acac)2M.cntnd.Ru6-(p-iPrC6H4Me)6(tpt)2(dhbq)3]6+: a trojan horse for cancer cells

Chat with Graph Search

Exploration and modulation of mechanical cues for enhanced cancer immunotherapy

Development of cysteine cathepsin inhibitors combined with cell type-specific delivery for the treatment of B-cell lymphoma and solid tumors

Cytokine-armed dendritic cell progenitors for antigen-agnostic cancer immunotherapy